Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer – final appraisal document

In this DRAFT guidance, darolutamide with androgen deprivation therapy (ADT) is recommended as an option for this indication, based on RCT evidence which shows that people taking darolutamide plus ADT have more time before their prostate cancer spreads compared with ADT alone.

Source:

National Institute for Health and Care Excellence